SGLT2 Inhibitors Poised to Potentially Reshape Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) Patient Care After AstraZeneca’s Farxiga Approval
According to new research from Spherix Global Insights, the FDA approval of Farxiga is likely to ignite a shift towards earlier CKD patient care with agents in the SGLT2 inhibitor class, including Invokana (Vifor/Janssen), Jardiance (Eli Lilly/Boehringer Ingelheim), and Steglatro (Merck) EXTON, Pa., / May 12, 2021 / PRNewswire – Nephrologists have long considered chronic […]
Oral Gepants Have Disrupted Acute Migraine Management and Look Next to Transform Preventive Treatment, According to Both Primary Care Physicians and Specialists
New research from Spherix Global Insights finds the impressive uptake of AbbVie’s Ubrelvy and Biohaven’s Nurtec ODT appears to have already blunted reliance on the subcutaneous CGRP monoclonal antibodies, with growth of Amgen/Novartis’ Aimovig, Teva’s Ajovy, and Eli Lilly’s Emgality all moderating EXTON, Pa., May 6, 2021 /PRNewswire/ — Both AbbVie’s (formerly Allergan, an AbbVie company) Ubrelvy […]
Spherix Global Insights Finds That Pipeline Therapies for Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis Will Need to Strike a Balance Between Liver Fat Reduction, Fibrosis Improvement, and Patient Safety as They Seek FDA Approval
Aside from an in-depth evaluation of the current diagnosis and management of NAFLD/NASH, ten pipeline product profiles were evaluated by gastroenterologists and hepatologists to assess strengths, weaknesses, and physician receptivity EXTON, Pa., May 5, 2021 /PRNewswire/ — Spherix recently surveyed 99 US gastroenterologists and 23 hepatologists and conducted ten qualitative interviews to assess the current and future […]
New Spherix Global Insights’ Patient Audit Highlights Key Differences Between Dermatologists’ and Rheumatologists’ Management of Psoriatic Arthritis, Focusing on Patients Recently Switched Between Advanced Systemic Treatment Brands
US dermatologists report increased confidence in treating psoriatic arthritis patients without a rheumatologist, and the two specialist groups report different drivers behind key treatment decisions in patient management EXTON, Pa., April 28, 2021 /PRNewswire/ – The past five or so years have seen a flurry of US biologic approvals for the treatment of psoriasis (PSO), […]
Robert Cowan, MD, on Sex and Race Disparities in Migraine Patients
Subgroup disparities such as sex and race are more significant among patients with migraine, according to the results of a recent study presented at the American Academy of Neurology (AAN) 2021 Virtual Meeting. The researchers utilized data from an annual cross-sectional patient chart audit of 1003 patients who were recently prescribed a calcitonin gene-related peptide […]
Chart review finds ’significant differences’ in migraine management by race, sex
Migraine diagnoses, treatment and management varied by race and sex among a sample of patients that was “evenly distributed” across the country, according to researchers. Robert Cowan, MD, FAAN, chief of the division of headache medicine and professor of neurology at Stanford University, presented findings of the cross-sectional chart review at the American Academy of Neurology […]
Understanding the Impact of Sex and Race on the Migraine Patient’s Journey in the United States: Analyses From an Annual Cross-Sectional Patient Chart Audit
Authors: Robert P. Cowan, MD, FAAN; Meg M. Stabb; Nicholas W. Robinson, PhD; Virginia R. Schobel, MSc OBJECTIVE: To determine whether subgroup disparities recognized in general society are reflected in subpopulations with migraine. BACKGROUND: It has been widely observed that disparities exist between various sub-groups in the U.S., including commonly noted disparities based on sex […]
Patients with Not Active Progressive Multiple Sclerosis in the United States: Profiling an Underserved Segment
Authors: Virginia R. Schobel, MSc; Meg M. Stabb OBJECTIVE: Compare clinical presentation, treatment history, and drivers of therapy choice of active and not active patients with progressive multiple sclerosis (MS). BACKGROUND: No disease-modifying therapy (DMT) is currently approved in the US for not active progressive MS, although multiple agents are currently in late-stage clinical development. […]
Tecfidera, Gilenya and Ocrevus Losing Favor as Switch Therapies in US, Spherix Finds
From: Multiple Sclerosis News Today By: Marta Figueiredo, PhD Tecfidera (dimethyl fumarate), Gilenya (fingolimod), and Ocrevus (ocrelizumab) are losing ground to more recent therapies among U.S. multiple sclerosis (MS) patients switching treatment, according to the latest Spherix Global Insights’ report…(read more).
Specialty Physicians Point to Permanent Changes Introduced by the COVID-19 Pandemic, Highlighting the Challenges that Lie Ahead for Pharmaceutical Manufacturers
Findings from the 16th wave of Spherix Global Insights’ COVID-19 research indicate that telemedicine is firmly entrenched, industry interaction remains largely virtual, and many practices are unlikely to return to pre-pandemic volumes EXTON, Pa., April 7, 2021 /PRNewswire/ — Since late March 2020, Spherix has been surveying specialty physicians (dermatologists, gastroenterologists, nephrologists, neurologists, and rheumatologists) in the […]
